IMUX

Immunic, Inc. (NASDAQ:IMUX) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in New York, New York. The company went public in April 2014 and focuses on developing selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases. Immunic operates as a research-focused organization with no current revenue-generating products, instead investing heavily in clinical trials to advance its pipeline of experimental treatments through various phases of regulatory approval.